ClearView cCAD is a software application designed to assist skilled physicians in analyzing breast ultrasound images. It automatically classifies shape and orientation characteristics of user-selected regions of interest. this device uses multivariate pattern recognition methods to perform characterization and classification of images.
Clinical role
Assists skilled physicians by automatically classifying shape and orientation of user-selected breast ultrasound regions of interest; results are displayed to the user for reporting, storage or modification and output as a DICOM overlay and/or PDF report.
Images and patients
Ultrasound · Breast
Key limitation
Scanner manufacturers: All
Overview status: Field-derived fact summary This section is assembled from the sourced field records below; it is not a source-reviewed editorial overview.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
Imaging and anatomyUltrasound · Breast
Workflow roleAssists skilled physicians by automatically classifying shape and orientation of user-selected breast ultrasound regions of interest; results are displayed to the user for reporting, storage or modification and output as a DICOM overlay and/or PDF report.
Required inputDICOM-compliant breast ultrasound images accepted from an ultrasound device, another DICOM source or PACS server, with a user-selected region of interest drawn as a bounding box around the area requiring analysis.
Output and human actionThe system outputs a DICOM compatible overlay (grayscale softcopy presentation state (GSPS)) and/or PDF report containing automatically classified shape and orientation characteristics of user-selected ROIs, ACR BI-RADS category assignment, and annotated lesion characteristics based on the ACR BI-RADS Ultrasound Lexicon Classification Form.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
ClearView cCAD is a software application designed to assist skilled physicians in analyzing breast ultrasound images. It automatically classifies shape and orientation characteristics of user-selected regions of interest. this device uses multivariate pattern recognition methods to perform characterization and classification of images.
Assists skilled physicians by automatically classifying shape and orientation of user-selected breast ultrasound regions of interest; results are displayed to the user for reporting, storage or modification and output as a DICOM overlay and/or PDF report.
Exact FDA submission
Checked 2026-11-14
Packet wording: "ClearView cCAD is a software application designed to assist skilled physicians in analyzing breast ultrasound images. ClearView cCAD automatically classifies shape and orientation characteristics of user-selected regions of interest (ROIs)." … "The results are displayed to the user on the monitor and can then be selected for automated reporting, storage, or modification. The output of this system will be a DICOM compatible overlay (e.g. grayscale softcopy presentation state (GSPS)) and/or PDF report". Read from the exact FDA decision document on 2026-11-14.
DICOM-compliant breast ultrasound images accepted from an ultrasound device, another DICOM source or PACS server, with a user-selected region of interest drawn as a bounding box around the area requiring analysis.
Exact FDA submission
Checked 2026-11-14
Packet wording: "The ClearView cCAD processing software is a platform agnostic web service that queries and accepts DICOM compliant digital medical files from an ultrasound device, another DICOM source, or PACS server." … "The user then selects an ROI to analyze by clicking and dragging a bounding box around the region requiring analysis.". Read from the exact FDA decision document on 2026-11-14.
The system outputs a DICOM compatible overlay (grayscale softcopy presentation state (GSPS)) and/or PDF report containing automatically classified shape and orientation characteristics of user-selected ROIs, ACR BI-RADS category assignment, and annotated lesion characteristics based on the ACR BI-RADS Ultrasound Lexicon Classification Form.
Exact FDA submission
Checked 2026-09-01
Clinical output reported in the exact-submission ACR model card.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
Study type: Stand-Alone Performance. Cases: 3000. Reference standard: Interpretation by Reviewing Clinician
Public source
Exact FDA submission
Checked 2026-09-01
Structured study metadata from the exact-submission ACR model card; this is not an independent evidence synthesis.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
ClearView cCAD regulatory performance study summary
DesignStand-Alone Performance
PopulationPopulation described in the exact-submission ACR model card
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K161959
Samplen=3000
IndependenceIndependence not established
K161959
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
FDA recall candidate Z-0820-2020 carries K161959, but the record identifies Koios DS Breast and Koios Medical rather than ClearView cCAD and ClearView Diagnostics. The candidate was reviewed and not published for this dossier; this does not establish absence of other safety information.
Public source
Exact FDA submission
Checked 2026-09-19
The exact identifier is insufficient when the FDA recall record's named product and firm do not match the directory dossier.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: DICOM-compliant breast ultrasound images accepted from an ultrasound device, another DICOM source or PACS server, with a user-selected region of interest drawn as a bounding box around the area requiring analysis.
Scope: Exact FDA submission. Packet wording: "The ClearView cCAD processing software is a platform agnostic web service that queries and accepts DICOM compliant digital medical files from an ultrasound device, another DICOM source, or PACS server." … "The user then selects an ROI to analyze by clicking and dragging a bounding box around the region requiring analysis.". Read from the exact FDA decision document on 2026-11-14.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The exact-submission ACR model card explicitly references DICOM in the described input, output, or workflow; exact interfaces, versions, and local compatibility require confirmation.
Scope: Exact FDA submission. Interoperability terms explicitly reported in the exact-submission ACR model card; interface versions and local compatibility still require confirmation.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. A legacy catalog deployment category, normalized to fixed categories, was not traced to the exact FDA decision document it cited, so it is not published as verified. Confirm the deployment model, hosting, data flow, and current commercial configuration with the vendor or an exact-submission source that states it.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-11-13 ·
Returned objects
Source context, not route validation: The system outputs a DICOM compatible overlay (grayscale softcopy presentation state (GSPS)) and/or PDF report containing automatically classified shape and orientation characteristics of user-selected ROIs, ACR BI-RADS category assignment, and annotated lesion characteristics based on the ACR BI-RADS Ultrasound Lexicon Classification Form.
Scope: Exact FDA submission. Clinical output reported in the exact-submission ACR model card.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: The system outputs a DICOM compatible overlay (grayscale softcopy presentation state (GSPS)) and/or PDF report containing automatically classified shape and orientation characteristics of user-selected ROIs, ACR BI-RADS category assignment, and annotated lesion characteristics based on the ACR BI-RADS Ultrasound Lexicon Classification Form.
Scope: Exact FDA submission. Clinical output reported in the exact-submission ACR model card.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact-submission ACR model card explicitly references DICOM in the described input, output, or workflow; exact interfaces, versions, and local compatibility require confirmation.
Exact FDA submission
Checked 2026-09-01
Interoperability terms explicitly reported in the exact-submission ACR model card; interface versions and local compatibility still require confirmation.
ACR AI Central provides an exact-submission model card for ClearView cCAD; FDA labeling remains controlling for clinical use, limitations, and performance.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-04Last searched
23Fields reviewed
9Source classes checked
0Awaiting review PubMed leads
0Awaiting review trial leads
0Unreviewed FDA recall leads
Exact-submission ACR model-card fields were normalized under the current provenance rules; vendor and independent-study confirmation remain distinct. Exact FDA scope controls clinical claims. ACR and official vendor material provide bounded catalog or product-family context. Candidate literature metadata remains a discovery queue until full-text identity, endpoint, population, and version review is completed. Automated exact-name discovery found 0 PubMed and 0 ClinicalTrials.gov candidate records. Candidates require human product and version matching; zero candidates is not evidence that no studies exist. 1 FDA recall candidate was manually reviewed: 0 published and 1 rejected as a neighboring or otherwise inapplicable version. Native FDA recall identifiers produced 1 postmarket candidate record; 1 has been reviewed (0 published, 1 rejected) and 0 remain unreviewed.
Candidate leads remain unpublished until a human confirms the exact product and tested version.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Care setting: Not publicly available - checked 2026-11-14 - Exact FDA submission
The exact FDA decision document was reviewed on 2026-11-14 and does not state a care setting or patient population for the subject device. Confirm intended sites and patients with the vendor and local policy.
Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission
No public price or quote for the exact K161959 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Deployment: Not verified - checked 2026-11-13 - Exact FDA submission
A legacy catalog deployment category, normalized to fixed categories, was not traced to the exact FDA decision document it cited, so it is not published as verified. Confirm the deployment model, hosting, data flow, and current commercial configuration with the vendor or an exact-submission source that states it.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not verified - checked 2026-09-08 - Exact FDA submission
Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-08 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: Koios Decision Support (DS) is an artificial intelligence (AI)/machine learning (ML)-based computer-aided diagnosis (CADx) software device intended for use as an adjunct to diagnostic ultrasound examinations of lesions or nodules suspicious for breast or thyroid cancer. Koios DS allows the user to select or confirm regions of interest (ROIs) within an image representing a single lesion or nodule to be analyzed. The software then automatically characterizes the selected image data to generate an AI/MLderived cancer risk assessment and selects applicable lexicon-based descriptors designed to improve overall diagnostic accuracy as well as reduce interpreting physician variability. Koios DS software may also be used as an image viewer of multi-modality digital images, including ultrasound and mammography. The software includes tools that allow users to adjust, measure and document images, and output into a structured report. Koios DS software is designed to assist trained interpreting physicians in analyzing the breast ultrasound images of adult (>= 22 years) female patients with soft tissue breast lesions and/or thyroid ultrasounds of all adult (>= 22 years) patients with thyroid nodules suspicious for cancer. When utilized by an interpreting physician who has completed the prescribed training, this device provides information that may be useful in recommending appropriate clinical management.
Authorized purpose: Koios DS is an artificial intelligence (AI)/machine learning (ML)-based computer-aided diagnosis (CADx) software device intended for use as an adjunct to diagnostic ultrasound examinations of lesions or nodules suspicious for breast or thyroid cancer. Koios DS allows the user to select or confirm regions of interest (ROIs) within an image representing a single lesion or nodule to be analyzed. The software then automatically characterizes the selected image data to generate an AI/ML-derived cancer risk assessment and selects applicable lexicon-based descriptors designed to improve overall diagnostic accuracy as well as reduce interpreting physician variability. Koios DS may also be used as an image viewer of multi-modality digital images, including ultrasound and mammography. The software includes tools that allow users to adjust, measure and document images, and output into a structured report. Koios DS software is designed to assist trained interpreting physicians in analyzing the breast ultrasound images of adult (>= 22 years) female patients with soft tissue breast lesions and/or thyroid ultrasounds of all adult (>= 22 years) patients with thyroid nodules suspicious for cancer. When utilized by an interpreting physician who has completed the prescribed training, this device provides information that may be useful in recommending appropriate clinical management. Limitations: Patient management decisions should not be made solely on the results of the Koios DS analysis. Koios DS software is not to be used for the evaluation of normal tissue, on sites of post-surgical excision, or images with doppler, elastography, or other overlays present in them. Koios DS software is not intended for use on portable handheld devices (e.g. smartphones or tablets) or as a primary diagnostic viewer of mammography images. The software does not predict the presence of the thyroid nodule margin descriptor, extra-thyroidal extension. In the event that this condition is present, the user may select this category manually from the margin descriptor list.
Authorized purpose: The QVCAD System is indicated as an aid to the reader during screening procedures in searching images of female breasts produced by the somo.v Automated Breast Ultrasound System, for screening mammography BI-RADS Assessment Category 1 or 2 and BI-RADS composition or density c or d, to detect mammography-occult lesions in regions not known to have suspicious findings. The indicators are not intended for diagnostic characterization of suspicious findings.
Modality
Ultrasound
Anatomy
Female breasts; mammography-occult lesions in non-suspicious regions
Authorized purpose: Assist qualified MSK-ultrasound professionals by highlighting supported joint anatomy and detection completeness on compatible adult ultrasound images; it is not a diagnostic device.
Modality
Ultrasound
Anatomy
Musculoskeletal joints: shoulder, elbow, wrist/hand, knee, and ankle/foot.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.